Evidence map›Paper›PMID 40593217›Full record

ReviewResults and problems in cell differentiation2025

Reversible Acetylation of Non-histone Proteins in Human Cancers.

Chunran Feng, Yiqun Zeng, Edward V Prochownik, Congqin Jiang, Youjun Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Results and problems in cell differentiation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chunran FengDepartment of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
Yiqun ZengDepartment of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
Edward V ProchownikDivision of Hematology/Oncology, Children's Hospital of Pittsburgh of UPMC, The Department of Microbiology and Molecular Genetics, The Pittsburgh Liver Research Center and The Hillman Cancer Center of UPMC, The University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Congqin JiangDepartment of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
Youjun LiDepartment of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China. liy7@whu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last three decades, we have witnessed great progress in uncovering the scope of reversible acetylation of non-histone proteins and understanding its mechanisms and functional consequences. In this review, we summarize the histone acetyltransferases (HATs)/deacetylases (HDACs) and their inhibitors, focusing on the role of reversible acetylation modification of non-histone proteins in tumor development while also exploring the application of HAT and HDAC inhibitors in cancer therapy.

Indexed as

Histone AcetyltransferasesHistone DeacetylasesNeoplasmsAcetylationAnimalsHistone Deacetylase InhibitorsHumansProtein Processing, Post-TranslationalHistone AcetyltransferasesHistone Deacetylase InhibitorsHistone DeacetylasesCancer therapyHistone acetyltransferasesHistone deacetylasesReversible acetylation of non-histone protein

Identifiers

PMID40593217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.